[PDF][PDF] Strategies to prevent or remediate cancer and treatment-related aging
JL Guida, T Agurs-Collins, TA Ahles… - JNCI: Journal of the …, 2021 - academic.oup.com
Up to 85% of adult cancer survivors and 99% of adult survivors of childhood cancer live with
an accumulation of chronic conditions, frailty, and/or cognitive impairments resulting from …
an accumulation of chronic conditions, frailty, and/or cognitive impairments resulting from …
[HTML][HTML] Window of opportunity trials in head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) has a large global burden of disease
and poor survival outcomes. Recent targeted therapies and immunotherapies have been …
and poor survival outcomes. Recent targeted therapies and immunotherapies have been …
Poor treatment tolerance in head and neck cancer patients with low muscle mass
MA Mascarella, T Patel, V Vendra, L Gardiner… - Head & …, 2022 - Wiley Online Library
Background We ascertain the role of a low cervical paraspinal skeletal muscle index
(CPSMI) as a biomarker for poor treatment tolerance in patients with operable mucosal head …
(CPSMI) as a biomarker for poor treatment tolerance in patients with operable mucosal head …
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111 …
SP Beyaert, AE Loriot, ND Huyghe, RM Goebbels… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: The EORTC-90111–24111 phase II window study evaluated afatinib
versus no preoperative treatment in patients with primary squamous cell carcinoma of the …
versus no preoperative treatment in patients with primary squamous cell carcinoma of the …
Discussion of trial designs for biomarker identification and validation through the use of case studies
FS Ou, MW An, AS Ruppert, SJ Mandrekar - JCO precision oncology, 2019 - ascopubs.org
With the launch of the National Cancer Institute's Precision Medicine Initiative in 2015, there
has been a shift to trial designs that tailor health care solutions to individual patients by …
has been a shift to trial designs that tailor health care solutions to individual patients by …
Early [18] FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status
M Porosnicu, A O'Brien Cox, JD Waltonen… - Frontiers in …, 2022 - frontiersin.org
Translational Relevance Evaluation of targeted therapies is urgently needed for the majority
of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who …
of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who …
Methoden klinischer Prüfung in der Onkologie
C Dittrich, L Edler, H Sindermann - Kompendium Internistische Onkologie …, 2022 - Springer
Fortschritt auf dem Gebiet der medizinischen Onkologie ist von Art und Sorgfalt der
Integration neuer Erkenntnisse in das bestehende Wissen abhängig. Dieser Prozess wird …
Integration neuer Erkenntnisse in das bestehende Wissen abhängig. Dieser Prozess wird …